Physiologically based pharmacokinetic/toxicokinetic modeling

Methods in Molecular Biology

Volumn 929, Issue , 2012, Pages 439-499

  Campbell, Jerry L ^a   Clewell, Rebecca A ^a   Gentry, P Robinan ^b   Andersen, Melvin E ^a   Clewell, Harvey J ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b ENVIRON INTERNATIONAL CORPORATION   (United States)

Author keywords

PBPK; Pharmacokinetics; Styrene

Indexed keywords

ALGORITHM; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; CHEMICAL SAFETY; COMPARTMENT MODEL; CONCENTRATION (PARAMETERS); IN VITRO STUDY; MATHEMATICAL MODEL; MICHAELIS MENTEN KINETICS; PARTITION COEFFICIENT; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PHYSIOLOGICALLY BASED TOXICOKINETIC MODEL; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STEADY STATE; TARGET ORGAN; TOXICOKINETICS;

EID: 84934439544     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-50-2_18     Document Type: Article

References (121)

1. Andersen ME (1981) Saturable metabolism and its relation to toxicity. Crit Rev Toxicol 9:105-150
2. Monro A (1992) What is an appropriate measure of exposure when testing drugs for carcinogenicity in rodents? Toxicol Appl Pharmacol 112:171-181
3. Andersen ME, Clewell HJ, Krishnan K (1995) Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. Risk Anal 15:533-537
4. Teorell T (1937) Kinetics of distribution of substances administered to the body. I. The extravascular mode of administration. Arch Int Pharmacodyn 57:205-225
5. Teorell T (1937) Kinetics of distribution of substances administered to the body. I. The intravascular mode of administration. Arch Int Pharmacodyn 57:226-240
6. O?Flaherty EJ (1987) Modeling: an introduction. National Research Council. In: Pharmacokinetics in risk assessment. Drinking water and health, vol 8. National Academy Press, Washington DC, pp. 27-35
7. Clewell HJ, Andersen ME (1985) Risk assessment extrapolations and physiological modeling. Toxicol Ind Health 1(4):111-131
8. Andersen ME, Clewell HJ, Gargas ML, Smith FA, Reitz RH (1987) Physiologically based pharmacokinetics and the risk assessment for methylene chloride. Toxicol Appl Pharmacol 87:185-205
9. Gerrity TR, Henry CJ (1990) Principles of route-to-route extrapolation for risk assessment. Elsevier, New York
10. Clewell HJ, Jarnot BM (1994) Incorporation of pharmacokinetics in non-carcinogenic risk assessment: Example with chloropentafluorobenzene. Risk Anal 14:265-276
11. Clewell HJ (1995) Incorporating biological information in quantitative risk assessment: an example with methylene chloride. Toxicology 102:83-94
12. Clewell HJ (1995) The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances. Toxicol Lett 79:207-217
13. ClewellHJ,Gentry PR,Gearhart JM,AllenBC, AndersenME(1995)Considering pharmacokinetic andmechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. Chemosphere 31:2561-2578
14. Clewell HJ, Andersen ME (1996) Use of physiologically-based pharmacokinetic modeling to investigate individual versus population risk. Toxicology 111:315-329
15. Clewell HJ III, Gentry PR, Gearhart JM (1997) Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. J Toxicol Environ Health 52:475-515
16. Himmelstein KJ, Lutz RJ (1979) A review of the application of physiologically based pharmacokinetic modeling. J Pharmacokinet Biopharm 7:127-145
17. Gerlowski LE, Jain RK (1983) Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72:1103-1126
18. Fiserova-Bergerova V (1983) Modeling of inhalation exposure to vapors: uptake distribution and elimination, vol 1 and 2. CRC, Boca Raton
19. Bischoff KB (1987) Physiologically based pharmacokinetic modeling. National Research Council. In: Pharmacokinetics in Risk Assessment. Drinking water and health, vol 8. National Academy Press, Washington, DC, pp. 36-61
20. Leung HW (1991) Development and utilization of physiologically based pharmacokinetic models for toxicological applications. J Toxicol Environ Health 32:247-267
21. Clewell HJ, Andersen ME (1986) A multiple dose-route physiological pharmacokinetic model for volatile chemicals using ACSL/PC. In: Cellier FD (ed) Languages for continuous system simulation. Society for Computer Simulation, San Diego, pp 95-101
22. Ramsey JC, Andersen ME (1984) A physiological model for the inhalation pharmacokinetics of inhaled styrene monomer in rats and humans. Toxicol Appl Pharmacol 73:159-175
23. Adolph EF (1949) Quantitative relations in the physiological constitutions of mammals. Science 109:579-585
24. Dedrick RL (1973) Animal scale-up. J Pharmacokinet Biopharm 1:435-461
25. Dedrick RL, Bischoff KB (1980) Species similarities in pharmacokinetics. Fed Proc 39:54-59
26. McDougal JN, Jepson GW, Clewell HJ, Mac- Naughton MG, Andersen ME (1986) A physiological pharmacokinetic model for dermal absorption of vapors in the rat. Toxicol Appl Pharmacol 85:286-294
27. Paustenbach DJ, Clewell HJ, Gargas ML, Andersen ME (1988) A physiologically based pharmacokinetic model for inhaled carbon tetrachloride. Toxicol Appl Pharmacol 96:191-211
28. Vinegar A, Seckel CS, Pollard DL, Kinkead ER, Conolly RB, Andersen ME (1992) Polychlorotrifluoroethylene (PCTFE) oligomer pharmacokinetics in Fischer 344 rats: development of a physiologically based model. Fundam Appl Toxicol 18:504-514
29. Clewell HJ, Andersen ME (1989) Improving toxicology testing protocols using computer simulations. Toxicol Lett 49:139-158
30. Bischoff KB, Brown RG (1966) Drug distribution in mammals. Chem Eng Prog Symp 62 (66):33-45
31. Astrand P, Rodahl K (1970) Textbook of work physiology. McGraw-Hill, New York
32. International Commission on Radiological Protection (ICRP) (1975) Report of the task group on reference man. ICRP Publication 23
33. Environmental Protection Agency (EPA) (1988) Reference physiological parameters in pharmacokinetic modeling. EPA/600/6-88/
34. Office of Health and Environmental Assessment, Washington, DC
35. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095
36. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997) Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13(4):407-484
37. Sato A, Nakajima T (1979) Partition coefficients of some aromatic hydrocarbons and ketones in water, blood and oil. Br J Ind Med 36:231-234
38. Sato A, Nakajima T (1979) A vial equilibration method to evaluate the drug metabolizing enzyme activity for volatile hydrocarbons. Toxicol Appl Pharmacol 47:41-46
39. Gargas ML, Burgess RJ, Voisard DE, Cason GH, Andersen ME (1989) Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 98:87-99
40. Jepson GW, Hoover DK, Black RK, McCafferty JD, Mahle DA, Gearhart JM (1994) A partition coefficient determination method for nonvolatile chemicals in biological tissues. Fundam Appl Toxicol 22:519-524
41. Clewell HJ (1993) Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing. Toxicol Lett 68:101-117
42. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA (1971) Methotrexate pharmacokinetics. J Pharm Sci 60:1128-1133
43. Farris FF, Dedrick RL, King FG (1988) Cisplatin pharmacokinetics: application of a physiological model. Toxicol Lett 43:117-137
44. Edginton AN, Theil FP, SchmittW,Willmann S (2008) Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 4:1143-1152
45. Andersen ME, Clewell HJ III, Gargas ML, MacNaughton MG, Reitz RH, Nolan R, McKenna M (1991) Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite carbon monoxide, and blood carboxyhemoglobin in rats and humans. Toxicol Appl Pharmacol 108:14-27
46. Andersen ME, Clewell HJ, Mahle DA, Gearhart JM (1994) Gas uptake studies of deuterium isotope effects on dichloromethane metabolism in female B6C3F1 mice in vivo. Toxicol Appl Pharmacol 128:158-165
47. Fisher J, Gargas M, Allen B, Andersen M (1991) Physiologically based pharmacokinetic modeling with trichloroethylene and itsmetabolite, trichloroacetic acid, in the rat andmouse. Toxicol Appl Pharmacol 109:183-195
48. Fisher JW, Allen BC (1993) Evaluating the risk of liver cancer in humans exposed to trichloroethylene using physiological models. Risk Anal 13:87-95
49. Allen BC, Fisher J (1993) Pharmacokinetic modeling of trichloroethylene and trichloroacetic acid in humans. Risk Anal 13:71-86
50. CorleyRA,MendralaAL,Smith FA, StaatsDA, Gargas ML, Conolly RB, Andersen ME, Reitz RH (1990) Development of a physiologically based pharmacokinetic model for chloroform. Toxicol Appl Pharmacol 103:512-527
51. Reitz RH, Mendrala AL, Corley RA, Quast JF, Gargas ML, Andersen ME, Staats DA, Conolly RB (1990) Estimating the risk of liver cancer associated with human exposures to chloroform using physiologically based pharmacokinetic modeling. Toxicol Appl Pharmacol 105:443-459
52. Johanson G (1986) Physiologically based pharmacokinetic modeling of inhaled 2- butoxyethanol in man. Toxicol Lett 34:23-31
53. Bungay PM, Dedrick RL, Matthews HB (1981) Enteric transport of chlordecone (Kepone) in the rat. J Pharmacokinet Biopharm 9:309-341
54. Tuey DB, Matthews HB (1980) Distribution and excretion of 2,20,4,40,5,50-hexabromobiphenyl in rats and man: pharmacokinetic model predictions. Toxicol Appl Pharmacol 53:420-431
55. Lutz RJ, Dedrick RL, Tuey D, Sipes IG, Anderson MW, Matthews HB (1984) Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model. Drug Metab Dispos 12(5):527-535
56. King FG, Dedrick RL, Collins JM, Matthews HB, Birnbaum LS (1983) Physiological model for the pharmacokinetics of 2,3,7,8- tetrachlorodibenzofuran in several species. Toxicol Appl Pharmacol 67:390-400
57. Leung HW, Ku RH, Paustenbach DJ, Andersen ME (1988) A physiologically based pharmacokinetic model for 2,3,7,8- tetrachlorodibenzo-p-dioxin in C57BL/6J and DBA/2J mice. Toxicol Lett 42:15-28
58. Andersen ME, Mills JJ, Gargas ML, Kedderis L, Birnbaum LS, Norbert D, Greenlee WF (1993) Modeling receptor-mediated processes with dioxin: implications for pharmacokinetics and risk assessment. Risk Anal 13 (1):25-36
59. O?Flaherty EJ (1991) Physiologically based models for bone seeking elements. I. Rat skeletal and bone growth. Toxicol Appl Pharmacol 111:299-312
60. O?Flaherty EJ (1991) Physiologically based models for bone seeking elements. II. Kinetics of lead disposition in rats. Toxicol Appl Pharmacol 111:313-331
61. O?Flaherty EJ (1991) Physiologically based models for bone seeking elements. III. Human skeletal and bone growth. Toxicol Appl Pharmacol 111:332-341
62. O?Flaherty EJ (1993) Physiologically based models for bone seeking elements. IV. Kinetics of lead disposition in humans. Toxicol Appl Pharmacol 118:16-29
63. O?Flaherty EJ (1995) Physiologically based models for bone seeking elements. V. Lead absorption and disposition in childhood. Toxicol Appl Pharmacol 131:297-308
64. Mann S, Droz PO, Vahter M (1996) A physiologically based pharmacokinetic model for arsenic exposure. I. Development in hamsters and rabbits. Toxicol Appl Pharmacol 137:8-22
65. Mann S, Droz PO, Vahter M (1996) A physiologically based pharmacokinetic model for arsenic exposure. II. Validation and application in humans. Toxicol Appl Pharmacol 140:471-486
66. Farris FF, Dedrick RL, Allen PV, Smith JC (1993) Physiological model for the pharmacokinetics of methyl mercury in the growing rat. Toxicol Appl Pharmacol 119:74-90
67. McMullin TS, Hanneman WH, Cranmer BK, Tessari JD, Andersen ME (2007) Oral absorption and oxidative metabolism of atrazine in rats evaluated by physiological modeling approaches. Toxicology 240:1-14
68. Lin Z, Fisher JW, Ross MK, Filipov NM (2011) A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. Toxicol Appl Pharmacol 251:16-31
69. Kirman CR, Hays SM, Kedderis GL, Gargas ML, Strother DE (2000) Improving cancer dose-response characterization by using physiologically based pharmacokinetic modeling: an analysis of pooled data for acrylonitrileinduced brain tumors to assess cancer potency in the rat. Risk Anal 20:135-151
70. Sweeney LM, Gargas ML, Strother DE, Kedderis GL (2003) Physiologically based pharmacokinetic model parameter estimation and sensitivity and variability analyses for acrylonitrile disposition in humans. Toxicol Sci 71:27-40
71. Takano R, Murayama N, Horiuchi K, Kitajima M, Kumamoto M, Shono F, Yamazaki H (2010) Blood concentrations of acrylonitrile in humans after oral administration extrapolated from in vivo rat pharmacokinetics, in vitro human metabolism, and physiologically based pharmacokinetic modeling. Regul Toxicol Pharmacol 58:252-258
72. Clewell RA, Merrill EA, Robinson PJ (2001) The use of physiologically based models to integrate diverse data sets and reduce uncertainty in the prediction of perchlorate and iodide kinetics across life stages and species. Toxicol Ind Health 17:210-222
73. Clewell RA, Merrill EA, Yu KO, Mahle DA, Sterner TR, Mattie DR, Robinson PJ, Fisher JW, Gearhart JM (2003) Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: a physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. Toxicol Sci 73:235-255
74. Clewell RA, Merrill EA, Yu KO, Mahle DA, Sterner TR, Fisher JW, Gearhart JM (2003) Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling. Toxicol Sci 74:416-436
75. Merrill EA, Clewell RA, Gearhart JM, Robinson PJ, Sterner TR, Yu KO, Mattie DR, Fisher JW (2003) PBPK predictions of perchlorate distribution and its effect on thyroid uptake of radioiodide in the male rat. Toxicol Sci 73:256-269
76. Merrill EA, Clewell RA, Robinson PJ, Jarabek AM, Gearhart JM, Sterner TR, Fisher JW (2005) PBPK model for radioactive iodide and perchlorate kinetics and perchlorateinduced inhibition of iodide uptake in humans. Toxicol Sci 83:25-43
77. McLanahan ED, Andersen ME, Campbell JL, Fisher JW (2009) Competitive inhibition of thyroidal uptake of dietary iodide by perchlorate does not describe perturbations in rat serum total T4 and TSH. Environ Health Perspect 117:731-738
78. Haddad S, Charest-Tardif G, Tardif R, Krishnan K (2000) Validation of a physiological modeling framework for simulating the toxicokinetics of chemicals in mixtures. Toxicol Appl Pharmacol 167:199-209
79. Haddad S, Beliveau M, Tardif R, Krishnan K (2001) A PBPK modeling-based approach to account for interactions in the health risk assessment of chemical mixtures. Toxicol Sci 63:125-131
80. Dennison JE, Andersen ME, Yang RS (2003) Characterization of the pharmacokinetics of gasoline using PBPK modeling with a complex mixtures chemical lumping approach. Inhal Toxicol 15:961-986
81. Dennison JE, Andersen ME, Clewell HJ, Yang RSH (2004) Development of a physiologically based pharmacokinetic model for volatile fractions of gasoline using chemical lumping analysis. Environ Sci Technol 38:5674-5681
82. Campbell JL, Fisher JW (2007) A PBPK modeling assessment of the competitive metabolic interactions of JP-8 vapor with two constituents, m-xylene and ethylbenzene. Inhal Toxicol 19:265-273
83. Rowland M, Balant L, Peck C (2004) Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29-30, 2002). AAPS PharmSci 6:56-67
84. Ramsey JC, Young JD (1978) Pharmacokinetics of inhaled styrene in rats and humans. Scand J Work Environ Health 4:84-91
85. Ramsey JC, Young JD, Karbowski R, Chenoweth MB, Mc Carty LP, Braun WH (1980) Pharmacokinetics of inhaled styrene in human volunteers. Toxicol Appl Pharmacol 53:54-63
86. Stewart RD, Dodd HC, Baretta ED, Schaffer AW (1968) Human exposure to styrene vapors. Arch Environ Health 16:656-662
87. Gearhart JM, Clewell HJ, Crump KS, Shipp AM, Silvers A (1995) Pharmacokinetic dose estimates of mercury in children and doseresponse curves of performance tests in a large epidemiological study. Water Air Soil Pollut 80:49-58
88. Gearhart JM, Jepson GW, Clewell HJ, Andersen ME, Conolly RB (1990) Physiologically based pharmacokinetic and pharmacodynamic model for the inhibition of acetylcholinesterase by diisopropylfluorophosphate. Toxicol Appl Pharmacol 106:295-310
89. Gearhart JM, Jepson GW, Clewell HJ, Andersen ME, Connoly RB (1995) A physiologically based pharmacokinetic model for the inhibition of acetylcholinesterase by organophosphate esters. Environ Health Perspect 102(11):51-60
90. Fisher JW, Whittaker TA, Taylor DH, Clewell HJ, AndersenME (1989) Physiologically based pharmacokineticmodeling of the pregnant rat: a multiroute exposuremodel for trichlorethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 99:395-414
91. Fisher JW, Whittaker TA, Taylor DH, Clewell HJ, Andersen ME (1990) Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup: a multiroute exposure model for trichlorethylene and its metabolite, trichloroacetic acid. Toxicol Appl Pharmacol 102:497-513
92. Luecke RH, Wosilait WD, Pearce BA, Young JF (1994) A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 49:90-103
93. Andersen ME, Gargas ML, Clewell HJ, Severyn KM (1987) Quantitative evaluation of the metabolic interactions between trichloroethylene and 1,1-dichloroethylene by gas uptake methods. Toxicol Appl Pharmacol 89:149-157
94. Mumtaz MM, Sipes IG, Clewell HJ, Yang RSH (1993) Risk assessment of chemical mixtures: biological and toxicologic issues. Fundam Appl Toxicol 21:258-269
95. Barton HA, Creech J.R., Godin CS, Randall GM, Seckel CS (1995) Chloroethylene mixtures: pharmacokinetic modeling and in vitro metabolism of vinyl chloride, trichloroethylene, and trans-1,2-dichloroethylene in rat. Toxicol Appl Pharmacol 130:237-247
96. Clewell HJ, Lee T, Carpenter RL (1994) Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. Risk Anal 14:521-531
97. Andersen ME, Gargas ML, Ramsey JC (1984) Inhalation pharmacokinetics: evaluating systemic extraction, total in vivo metabolism and the time course of enzyme induction for inhaled styrene in rats based on arterial blood: inhaled air concentration ratios. Toxicol Appl Pharmacol 73:176-187
98. Andersen ME, Clewell HJ, Frederick CB (1995) Applying simulation modeling to problems in toxicology and risk assessment-a short perspective. Toxicol Appl Pharmacol 133:181-187
99. Vinegar A, Winsett DW, Andersen ME, Conolly RB (1990) Use of a physiologically based pharmacokinetic model and computer simulation for retrospective assessment of exposure to volatile toxicants. Inhal Toxicol 2:119-128
100. Vinegar A, JepsonGW(1996) Cardiac sensitization thresholds of halon replacement chemicals predicted in humans by physiologicallybased pharmacokinetic modeling. Risk Anal 16:571-579
101. Clewell HJ, Andersen ME, Wills RJ, Latriano L (1997) A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J Am Acad Dermatol 36:S77-S85
102. Fiserova-Bergerova V (1975) Biological- mathematical modeling of chronic toxicity. AMRL-TR-75-5. Aerospace Medical Research Laboratory, Wright-Patterson Air Force Base
103. GargasML,AndersenME(1989)Determining kinetic constants of chlorinated ethanemetabolism in the rat from rates of exhalation. Toxicol Appl Pharmacol 97:230-246
104. Gargas ML, Andersen ME, Clewell HJ (1986) A physiologically-based simulation approach for determining metabolic constants from gas uptake data. Toxicol Appl Pharmacol 86:341-352
105. Gargas ML, Clewell HJ, Andersen ME (1990) Gas uptake techniques and the rates of metabolism of chloromethanes, chloroethanes, and chloroethylenes in the rat. Inhal Toxicol 2:295-319
106. Reitz RH, Mendrala AL, Guengerich FP (1989) In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically-based pharmacokinetic models. Toxicol Appl Pharmacol 97:230-246
107. Filser JG, Bolt HM (1979) Pharmacokinetics of halogenated ethylenes in rats. Arch Toxicol 42:123-136
108. Andersen ME, Gargas ML, Jones RA, Jenkins LH Jr (1980) Determination of the kinetic constants of metabolism of inhaled toxicant in vivo based on gas uptake measurements. Toxicol Appl Pharmacol 54:100-116
109. Gargas ML, Clewell HJ, Andersen ME (1986) Metabolism of inhaled dihalomethanes in vivo: differentiation of kinetic constants for two independent pathways. Toxicol Appl Pharmacol 82:211-223
110. Watanabe P, Mc Gown G, Gehring P (1976) Fate of [14] vinyl chloride after single oral administration in rats. Toxicol Appl Pharmacol 36:339-352
111. Gargas ML, Andersen ME (1982) Metabolism of inhaled brominated hydrocarbons: validation of gas uptake results by determination of a stable metabolite. Toxicol Appl Pharmacol 66:55-68
112. Lam G, Chen M, Chiou WL (1981) Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. J Pharm Sci 71(4):454-456
113. O?Flaherty EJ (1995) PBPK modeling for metals. Examples with lead, uranium, and chromium. Toxicol Lett 82-83:367-372
114. Environmental Protection Agency (EPA) (1992) EPA request for comments on draft report of cross-species scaling factor for cancer risk assessment. Fed Reg 57:24152
115. Carson ER, Cobelli C, Finkelstein L (1983) The mathematical modeling of metabolic and endocrine systems model formulation, identification, and validation. Wiley, New York
116. Rescigno A, Beck JS (1987) The use and abuse of models. J Pharmacokinet Biopharm 15:327-340
117. Yates FE (1978) Good manners in good modeling: mathematical models and computer simulations of physiological systems. Am J Physiol 234:R159-R160
118. Clewell HJ (1995) The use of physiologically based pharmacokinetic modeling in risk assessment: a case study with methylene chloride. In: Olin S, Farland W, Park C, Rhomberg L, Scheuplein R, Starr T, Wilson J (eds) Low-dose extrapolation of cancer risks: issues and perspectives. ILSI, Washington, DC
119. Allen BC, Covington TR, Clewell HJ (1996) Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. Toxicology 111:289-303
120. Clewell HJ, Andersen ME (1994) Physiologically-based pharmacokinetic modeling and bioactivation of xenobiotics. Toxicol Ind Health 10:1-24
121. D?Souza RW, Francis WR, Andersen ME (1988) Physiological model for tissue glutathione depletion and increased resynthesis after ethylene dichloride exposure. J Pharmacol Exp Ther 245:563-568